Site updated at Wednesday, 22 June 2016

Living with Dementia


Eli Lilly Announces FDA Approval of Amyvid For Alzheimer’s Assessment

Eli Lilly and Company (NYSE: LLY) and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly, today announced the U.S. Food and Drug Administration (FDA) approval of Amyvid™, a radioactive diagnostic agent indicated for brain imaging of beta-amyloid plaques in patients with cognitive impairment who are being evaluated for Alzheimer’s Disease and other causes… Eli Lilly Announces FDA Approval of Amyvid For Alzheimer’s Assessment   

FDA OKs Agent to Differentiate Alzheimer’s

The FDA has approved the radioactive diagnostic agent florbetapir (Amyvid) for evaluation of the causes of cognitive decline, including Alzheimer’s disease, according to Eli Lilly, developer of the compound.

Florbetapir is used in conjunction with positron emission tomography to evaluate the burden of amyloid plaques in the brain, according to Daniel Skovronsky, MD, PhD,… FDA OKs Agent to Differentiate Alzheimer’s   

Living With Dementia

tavi2 - antioxidants1 - quetiapine1 - semantic dementia1 - hiv dementia1 - dementias first signs1 - mixed forms1 - adam101 - neurotransmitter1 - myelination1 - alpha-synuclein diseases1 - early symptoms of alzheimer’s disease1 - deep brain stimulation2 - protein alpha-synuclein1 - dementia awareness week1 - journal of the american geriatrics society1 - frontal lobe dementia1 - parkinsonian brain1 - rates of dementia1 - long-term memory1 - dotage1 - sleep tied to alzheimer's1 - hormone therapy1 - great mimicker1 - huntington's disease8 - early signs of dementia1 - iron lady1 - management of delirium1 - disinhibition1 - alzheimer's markers1 -